0001100682false00011006822024-05-082024-05-08

Date of Report (Date of earliest event reported)

(Exact Name of Registrant as Specified in Charter)

(Address of Principal Executive Offices) (Zip Code)

(Registrant’s Telephone Number, including Area Code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Charles River Laboratories International, Inc. (the "Company") held its Annual Meeting of Shareholders on May 8, 2024. For more information on the following proposals, see the Company’s proxy statement dated March 29, 2024. At the Company’s Annual Meeting, the following proposals were adopted by the votes specified below:

(a) The following eleven (11) directors were elected to serve until our 2025 Annual Meeting of Shareholders and received the number of votes listed opposite each of their names below:

			Number of Shares Voted For			Number of Shares Voted Against			Number of Shares Abstained			Broker Non-Votes
James C. Foster			43,667,281			2,380,275			140,644			2,038,517
Nancy C. Andrews			45,474,179			688,931			25,090			2,038,517
Robert J. Bertolini			44,599,861			1,562,940			25,399			2,038,517
Reshema Kemps-Polanco			46,096,094			66,865			25,241			2,038,517
Deborah T. Kochevar			43,252,303			2,910,578			25,319			2,038,517
George Llado, Sr.			45,449,038			713,929			25,233			2,038,517
Martin W. Mackay			39,753,364			6,409,765			25,071			2,038,517
George E. Massaro			43,532,473			2,629,967			25,760			2,038,517
Craig B. Thompson			46,041,753			121,233			25,214			2,038,517
Richard F. Wallman			44,122,023			2,040,680			25,497			2,038,517
Virginia M. Wilson			45,342,311			820,481			25,408			2,038,517

(b) The shareholders approved, on an advisory, non-binding basis, the compensation of our named executive officers.

For			Against			Abstain			Broker Non-Votes
43,833,503			2,299,362			55,335			2,038,517

(c) The shareholders approved the ratification of the appointment of PricewaterhouseCoopers LLP as our independent auditors for fiscal 2024.

For			Against			Abstain			Broker Non-Votes
45,612,837			2,586,704			27,176			0

(e) The shareholders did not approve the shareholder proposal submitted by PETA to publish a report on non-human primates imported by the Company.

Computershare Trust Company, N.A., our transfer agent, acted as independent proxy tabulator and Inspector of Election at the Annual Meeting of Shareholders.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.